Genmab — Januar 2023
-
-
Transactions with shares and linked
securities in Genmab A/S made by managerial employees and their closely associated persons https://www.proinvestor.com/investornyt/922570/transactions-with-shares-and-linked-securities-in-genmab-a-s-made-by-managerial-employees-and-their-closely-associated-persons -
USA/lukning: Apple og Tesla ødelagde nytårsfesten https://www.proinvestor.com/investornyt/922650/usa-lukning-apple-og-tesla-odelagde-nytarsfesten
-
Genmab A/S (NASDAQ:GMAB - Get Rating) had its target price increased by investment analysts at JPMorgan Chase & Co. from 3,450.00 to 3,600.00 in a research note issued on Tuesday, The Fly reports. The firm currently has an "overweight" rating on the stock. https://www.marketbeat.com/instant-alerts/nasdaq-gmab-a-buy-or-sell-right-now-2023-01/
-
Hummingbird -which previously tried to work with Genmab's Duobody technology- now wants to try Synaffix ADC tech, just like Genmab. Funny that Genmabs deal with Synaffix was also on Jan 4, last year
https://hummingbirdbioscience.com/hummingbird-bioscience-and-synaffix-enter-license-agreement-to-develop-a-next-generation-antibody-drug-conjugate-adc-program/ -
J&J Q4 resultat 24 jan. https://www.jnj.com/johnson-johnson-to-host-investor-conference-call-on-fourth-quarter-results_
-
Ser frem til konferencen i næste uge. Mon ikke vi bliver lidt klogere på 1046 og især 1042. Det var jo nogle gevaldige udvidelser af studiet vi så fornylig. Og R&D dagen bragte ikke meget nyt. Jeg tror de kører på med begge stoffer, og at vi snart kan varme op til store forventninger til 1042.
-
Godmorgen.
-
-
Tjaa - iøvrigt skriver MarketWire og Børsen at JP Morgan har det højeste mål af alle. For det første er der flere i det leje, og Morgan ligger kun nr 3 skarpt efterfulgt af Bank off America, Carnegie og Kempen - men det er jo ikke sådan at være en skarp journalist.
-
Syntes det er svært at tolke salg/køb, når vi ikke kan se, hvem der reelt handler. Derudover er der jo mange motiver for salg/køb, som ikke nødvedigvis er rationelle eller logiske, set ud fra vores synspunkter som investor, med fokus på højest mulig kurs.
-
J&J's consumer health unit Kenvue files for IPO, moving closer to spin-off https://www.reuters.com/markets/deals/jjs-consumer-health-unit-kenvue-files-us-ipo-2023-01-04/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind